ViferaXS

ViferaXS specializes in next-generation personalized therapeutic vaccinations for cancer patients using a proprietary immunopeptidome-based antigen discovery platform. This approach allows rapid identification of naturally presented mutated and non-mutated tumor antigens directly from patient tumors. Their lead technology combines these peptides with their proprietary XS15 adjuvant to induce potent T cell responses. The company has four ongoing clinical trials evaluating its peptide-based T cell activators, with additional pipeline activities in infectious diseases. They also offer immunopeptidome analysis services to academic and industry partners.